Paula Cloghessy
Net worth: 33 943 $ as of 2024-04-29
Profile
Paula A.
Cloghessy served as the Senior Vice President-Human Resources at Translate Bio, Inc. from 2017 to 2021.
Prior to that, she was the Vice President-Human Resources at Joule Unlimited Technologies, Inc. from 2010 to 2016.
In 2022, she will be the Chief People Officer & Executive Vice President at Seres Therapeutics, Inc. Ms. Cloghessy obtained her undergraduate degree from the University of Massachusetts.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SERES THERAPEUTICS INC
0.03% | 2023-10-29 | 45,684 ( 0.03% ) | 33 943 $ | 2024-04-29 |
Former positions of Paula Cloghessy
| Companies | Position | End |
|---|---|---|
| SERES THERAPEUTICS, INC. | Human Resources Officer | 2023-12-30 |
| TRANSLATE BIO, INC. | Human Resources Officer | 2021-09-13 |
Joule Unlimited Technologies, Inc.
 Joule Unlimited Technologies, Inc. Industrial SpecialtiesProcess Industries Joule Unlimited Technologies, Inc. produces renewable fuels and chemicals. It offers a technology platform for liquid fuel from the Sun. The company was founded by Noubar B. Afeyan in 2007 and is headquartered in Bedford, MA. | Human Resources Officer | 2016-03-31 |
Training of Paula Cloghessy
| University of Massachusetts | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SERES THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Joule Unlimited Technologies, Inc.
Joule Unlimited Technologies, Inc. Industrial SpecialtiesProcess Industries Joule Unlimited Technologies, Inc. produces renewable fuels and chemicals. It offers a technology platform for liquid fuel from the Sun. The company was founded by Noubar B. Afeyan in 2007 and is headquartered in Bedford, MA. | Process Industries |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Paula Cloghessy
